Open AccessBovine Blood and Neuromuscular Paralysis as a Bridge to Recovery in a Patent with Severe Autoimmune Hemolytic Anemia
Author(s) -
Pachinburavan Monvasi,
Marik Paul E.
Publication year - 2008
Publication title -
clinical and translational science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.303
H-Index - 44
eISSN - 1752-8062
pISSN - 1752-8054
DOI - 10.1111/j.1752-8062.2008.00006.x
Subject(s) - medicine , autoimmune hemolytic anemia , hemoglobin , anemia , immunology , blood substitute , paralysis , antibody , blood transfusion , intensive care medicine , surgery
Hemoglobin solutions have several advantages as substitutes for erythrocyte transfusions. They have a prolonged shelf life, do not require cross‐matching, are associated with few transfusion reactions, and are effective in delivering oxygen to the tissues. Despite the potential clinical utility of these solutions, they have not achieved widespread use. HbOC‐201 (Hemopure, Biopure, Cambridge, MA, USA) is a bovine hemoglobin solution that has been FDA approved for compassionate use in Jehovah's witness patients requiring transfusions. Here we report a case of a patient with hemoglobin H disease who developed a severe life‐threatening mixed warm and cold antibody mediated autoimmune hemolytic anemia (AIHA) and immune thrombocytopenia (ITP) who was successfully treated with HbOC‐201 as an adjunct to blood transfusion.